Biblio

Found 106 results

Filters: Author is others [Clear All Filters]

2014

J. N. Weinstein, Kim, J., Creighton, C. J., Akbani, R., Hoadley, K. A., Kim, W. Y., Morgan, M. B., Hinoue, T., Rosenberg, J. E., Bajorin, D. F., and , “Comprehensive molecular profiling of urothelial bladder cancer at the DNA, RNA, and protein levels: A TCGA project.”. American Society of Clinical Oncology, 2014.

P. C. Boutros, Ewing, A. D., Ellrott, K., Norman, T. C., Dang, K. K., Hu, Y., Kellen, M. R., Suver, C., J Bare, C., Stein, L. D., and , “Global optimization of somatic variant identification in cancer genomes with a global community challenge”, Nature genetics, vol. 46, p. 318, 2014.

J. J. Alumkal, Heiser, L., Beer, T. M., Small, E. Jay, Baertsch, R., Stuart, J., King, C., Korkola, J., Cetnar, J., Graff, J. Nicole, and , “Identifying enzalutamide resistance mechanisms in men with castration-resistant prostate cancer.”. American Society of Clinical Oncology, 2014.

N. Agrawal, Akbani, R., B Aksoy, A., Ally, A., Arachchi, H., Asa, S. L., J Auman, T., Balasundaram, M., Balu, S., Baylin, S. B., and , “Integrated genomic characterization of papillary thyroid carcinoma”, Cell, vol. 159, pp. 676–690, 2014.

G. Thomas, Youngren, J., Ryan, C. J., Beer, T. M., Gleave, M. Edwin, Evans, C. P., Stuart, J., Rettig, M., Toschi, A., Foye, A., and , “Molecular profiling of metastatic castration-resistant prostate cancer (mCRPC): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).”. American Society of Clinical Oncology, 2014.

K. A. Hoadley, Yau, C., Wolf, D. M., Cherniack, A. D., Tamborero, D., Ng, S., Leiserson, M. D. M., Niu, B., McLellan, M. D., Uzunangelov, V., and , “Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin”, Cell, vol. 158, pp. 929–944, 2014.

A. Bivol, Baertsch, R., Sokolov, A., Paull, E., Newton, Y., Goldstein, T. C., Foye, A., Pourmand, N., Youngren, J., Parulkar, R., and , “Pathway-based signature analysis of RNA-seq data to reveal new targetable avenues for metastatic castration-resistant prostate cancer (mCRPC) patients (pts): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).”. American Society of Clinical Oncology, 2014.

E. Jay Small, Youngren, J., Beer, T. M., Ryan, C. J., Thomas, G., Pourmand, N., Reiter, R. Evan, Alumkal, J. J., Stuart, J. M., Evans, C. P., and , “The molecular and pathway characterization of patients with metastatic castration resistant prostate cancer (mCRPC) refractory to therapy with abiraterone acetate or enzalutamide: Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream”. American Society of Clinical Oncology, 2014.

2013

L. M. Heiser, Shaw, C. A., Wang, N. J., Grasso, C., Anur, P., Ng, S., Goldstein, T., Spellman, P. T., Stuart, J., Osborne, K., and , “Acquired therapeutic resistance is mediated by deregulation of multiple pathways.”. American Association for Cancer Research, 2013.

A. Gonzalez-Perez, Mustonen, V., Reva, B., Ritchie, G. R. S., Creixell, P., Karchin, R., Vazquez, M., J Fink, L., Kassahn, K. S., Pearson, J. V., and , “Computational approaches to identify functional genetic variants in cancer genomes”, Nature methods, vol. 10, p. 723, 2013.

D. A. Levine, Network, C. Genome Atl, and , “Integrated genomic characterization of endometrial carcinoma”, Nature, vol. 497, p. 67, 2013.

J. N. Weinstein, Collisson, E. A., Mills, G. B., Shaw, K. R. Mills, Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., Stuart, J. M., Network, C. Genome Atl, and , “The cancer genome atlas pan-cancer analysis project”, Nature genetics, vol. 45, p. 1113, 2013.

C. W. Brennan, Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., J Sanborn, Z., Berman, S. H., and , “The somatic genomic landscape of glioblastoma”, Cell, vol. 155, pp. 462–477, 2013.

2012

C. Genome Atl Network and , “Comprehensive genomic characterization of squamous cell lung cancers”, Nature, vol. 489, p. 519, 2012.

C. Genome Atl Network and , “Comprehensive molecular characterization of human colon and rectal cancer”, Nature, vol. 487, p. 330, 2012.

C. Genome Atl Network and , “Comprehensive molecular portraits of human breast tumours”, Nature, vol. 490, p. 61, 2012.

E. Collisson, Ng, S., Collisson, E. A., Sokolov, A., Goldstein, T., Lopez-Bigas, N., Benz, C., Haussler, D., Stuart, J. M., and , “PARADIGM-SHIFT predicts the function of mutations in multiple cancers using pathway impact analysis”, 2012.

S. Ng, Thusberg, J., Benz, S., Vaske, C., Ellrott, K., Zhu, J., Yau, C., Collisson, E., Mooney, S., Benz, C., and , “Predicting the impact of mutations in cancer using an integrated pathway approach”. American Association for Cancer Research, 2012.

L. M. Heiser, Sadanandam, A., Kuo, W. - L., Benz, S. C., Goldstein, T. C., Ng, S., Gibb, W. J., Wang, N. J., Ziyad, S., Tong, F., and , “Subtype and pathway specific responses to anticancer compounds in breast cancer”, Proceedings of the National Academy of Sciences, vol. 109, pp. 2724–2729, 2012.

M. James Ellis, Ding, L., Shen, D., Luo, J., Suman, V. J., Goiffon, R. J., Wallis, J. W., Goldstein, T. C., Chen, K., Allred, D. Craig, and , “Whole genome sequencing to characterize luminal-type breast cancer.”. American Society of Clinical Oncology, 2012.

M. J. Ellis, Ding, L., Shen, D., Luo, J., Suman, V. J., Wallis, J. W., Van Tine, B. A., Hoog, J., Goiffon, R. J., Goldstein, T. C., and , “Whole-genome analysis informs breast cancer response to aromatase inhibition”, Nature, vol. 486, p. 353, 2012.

2011

S. Ng, Vaske, C., Benz, S., Durbin, J., Szeto, C., Heiser, L., Wang, N., Korkola, J., Bayani, N., Spellman, P., and , “Constructing pathway based predictors of cancer clinical outcome”. American Association for Cancer Research, 2011.

C. Genome Atl Network and , “Integrated genomic analyses of ovarian carcinoma”, Nature, vol. 474, p. 609, 2011.

D. M. Wolf, Yau, C., Benz, S., Vaske, C., Stuart, J., Roy, R., Olshen, A., Boudreau, A., Haussler, D., Gray, J., and , “P1-06-09: Patient-Specific Integrative Pathway Analysis Using PARADIGM Identifies Key Activities in I-SPY 1 Breast Cancer Patients (CALGB 150007/150012; ACRIN 6657).”. American Association for Cancer Research, 2011.

J. Zhu, J Sanborn, Z., Benz, S. C., Craft, B., Szeto, C., Kober, K. M., Goldman, M., Meyer, L., Vaske, C., Collisson, E., and , “The UCSC Cancer Genomics Browser”. American Association for Cancer Research, 2011.

Pages